Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: Comparison to computed tomography

Investigative Radiology

Volumn 44, Issue 10, 2009, Pages 683-690

  Kwee, Thomas C ^a   Quarles Van Ufford, Henriette M E ^a   Beek, Frederik J ^a   Takahara, Taro ^a   Uiterwaal, Cuno S ^a   Bierings, Marc B ^a   Ludwig, Inge ^a   Fijnheer, Rob ^b   Nievelstein, Rutger A J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b MEANDER MEDICAL CENTER   (Netherlands)

Author keywords

Computed tomography; Diffusion weighted imaging; Hodgkin disease; Malignant lymphoma; Non Hodgkin lymphoma; Whole body magnetic resonance imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPHOMA; MALE; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOLOGIST; SCHOOL CHILD; WHOLE BODY MRI;

EID: 70349661882     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181afbb36     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
2. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111:504-516.
3. Brenner DJ, Hall EJ. Computed tomography-an increasing source of radiation exposure. N Engl J Med. 2007;357:2277-2284.
4. Semelka RC, Armao DM, Elias J Jr, et al. Imaging strategies to reduce the risk of radiation in CT studies, including selective substitution with MRI. J Magn Reson Imaging. 2007;25:900-909.
5. Barentsz J, Takahashi S, Oyen W, et al. Commonly used imaging techniques for diagnosis and staging. J Clin Oncol. 2006;24:3234-3244.
6. Executive Summary. In: Board on Radiation Effects Research Division on Earth and Life Studies, ed. Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: National Academy Press; 2005.
7. Namasivayam S, Kalra MK, Torres WE, et al. Adverse reactions to intravenous iodinated contrast media: a primer for radiologists. Emerg Radiol. 2006;12:210-215. (Pubitemid 44065552)
8. Lauenstein TC, Semelka RC. Emerging techniques: whole-body screening and staging with MRI. J Magn Reson Imaging. 2006;24:489-498.
9. Plathow C, Aschoff P, Lichy MP, et al. Positron emission tomography/ computed tomography and whole-body magnetic resonance imaging in staging of advanced non-small-cell lung cancer initial results. Invest Radiol. 2008;43:290-297.
10. Lichy MP, Aschoff P, Plathow C, et al. Tumor detection by diffusion-weighted MRI and ADC-mapping initial clinical experiences in comparison to PET-CT. Invest Radiol. 2007;42:605-613.
11. Schmidt GP, Wintersperger B, Graser A, et al. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study. Invest Radiol. 2007;42:449-459.
12. Schmidt GP, Baur-Melnyk A, Herzog P, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol. 2005;40:743-753.
13. Schlemmer HP, Schäfer J, Pfannenberg C, et al. Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: initial experiences. Invest Radiol. 2005;40:64-71.
14. Lauenstein TC, Goehde SC, Herborn CU, et al. Whole-body MR imaging: evaluation of patients for metastases. Radiology. 2004;233:139-148.
15. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003; 290:3199-3206.
16. Kwee TC, Takahara T, Ochiai R, et al. Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol. 2008;18:1937-1952.
17. Takahara T, Imai Y, Yamashita T, et al. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med. 2004;22:275-282.
18. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
19. Armitage JO. Staging non-Hodgkin lymphoma. CA Cancer J Clin. 2005;55: 368-376.
20. Brunning RD, Bloomfield CD, McKenna RW, et al. Bilateral trephine bone marrow biopsies in lymphoma and other neoplastic diseases. Ann Intern Med. 1975;82:365-366.
21. Coller BS, Chabner BA, Gralnick HR. Frequencies and patterns of bone marrow involvement in non-Hodgkin lymphomas: observations on the value of bilateral biopsies. Am J Hematol. 1977;3:105-119.
22. Haddy TB, Parker RI, Magrath IT. Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging. Med Pediatr Oncol. 1989;17:418-423.
23. Wang J, Weiss LM, Chang KL, et al. Diagnostic utility of bilateral bone marrow examination: significance of morphologic and ancillary technique study in malignancy. Cancer. 2002;94:1522-1531.
24. Pakos EE, Fotopoulos AD, Ioannidis JP. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46:958-963.
25. Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110:652-659.
26. Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875-3876.
27. Connors JM. State-of-the-art therapeutics: Hodgkin's lymphoma. J Clin Oncol. 2005;23:6400-6408.
28. Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc. 2005;80:1087-1097.
29. Hennessy BT, Hanrahan EO, Daly PA. Non-Hodgkin lymphoma: an update. Lancet Oncol. 2004;5:341-353.
30. Brennan DD, Gleeson T, Coate LE, et al. A comparison of whole-body MRI and CT for the staging of lymphoma. Am J Roentgenol. 2005;185:711-716.
31. Kellenberger CJ, Miller SF, Khan M, et al. Initial experience with FSE STIR whole-body MR imaging for staging lymphoma in children. Eur Radiol. 2004;14:1829-1841.
32. Vinnicombe SJ, Reznek RH. Computerised tomography in the staging of Hodgkin's disease and non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging. 2003;30(suppl 1):S42-S55.
33. Kwee TC, Kwee RM, Verdonck LF, et al. Magnetic resonance imaging for the detection of bone marrow involvement in malignant lymphoma. Br J Haematol. 2008;141:60-68.
34. Bain BJ. Morbidity associated with bone marrow aspiration and trephine biopsy-a review of UK data for 2004. Haematologica. 2006;91:1293-1294.
35. Sumi M, Sakihama N, Sumi T, et al. Discrimination of metastatic cervical lymph nodes with diffusion-weighted MR imaging in patients with head and neck cancer. AJNR Am J Neuroradiol. 2003;24:1627-1634.
36. Sumi M, Van Cauteren M, Nakamura T. MR microimaging of benign and malignant nodes in the neck. Am J Roentgenol. 2006;186:749-757.
37. Abdel Razek AA, Soliman NY, Elkhamary S, et al. Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol. 2006;16: 1468-1477.
38. Torabi M, Aquino SL, Harisinghani MG. Current concepts in lymph node imaging. J Nucl Med. 2004;45:1509-1518.
39. Kreel L. The EMI whole body scanner in the demonstration of lymph node enlargement. Clin Radiol. 1976;27:421-429.
40. Plathow C, Walz M, Lichy MP, et al. Cost considerations for whole-body MRI and PET/CT as part of oncologic staging. Radiologe. 2008;48:384-396.
41. Thomsen HS. Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol. 2006;16:2619-2621.